Wei Deng

Wei Deng is an Associate Professor and Deputy Head of School (Research) in the School of Biomedical Engineering at the University of Technology Sydney (UTS). Her research focuses on cancer nanotechnology, nanobiotechnology, and gene engineering, with significant contributions to radiation-activated chemotherapy (RAC) via liposomes and CRISPR-based therapies. She has pioneered treatments for rectal and breast cancers, including the development of patented RAC systems that reduce chemotherapy toxicity. Her work has led to the founding of biotech startup EosGene Pty Ltd for diabetic retinopathy therapies. Deng holds a PhD from Macquarie University and has attracted over $3.7M in grants from ARC, NHMRC, and Cancer Institute NSW. She leads interdisciplinary teams and contributes to global collaborations, including partnerships with UNSW and HK Winhealth Pharma Group. Her research spans drug/gene delivery systems, CRISPR biosensors, and nanoparticle engineering, emphasizing translational medicine and industrial challenges.

• Education: PhD in Biomedical Engineering, Macquarie University (Sydney)
• Leadership Roles: Deputy Head of School, Research; Co-founder of EosGene Pty Ltd
• Awards: DECRA Fellowship (ARC), Cancer Institute NSW Career Development Fellowship
• Key Projects: RAC liposomes (Patents US 12036282, Europe 3720422), CRISPR-based pathogen sensors, X-ray triggered PDT platforms

Her research bridges nanotechnology and clinical applications, with 62 refereed publications (h-index 26) and 87% in top-tier journals. She actively supervises postgraduate research in CRISPR therapies, CAR T cell engineering, and targeted drug delivery.